Transaction DateRecipientSharesTypePriceValue
4th January 2021Raymond Debbane724Grant/award etc.$0.00
16th December 2020Public Equities, L.P. Invus10,937,500Open or private purchase$3.20$35,000,000.00
16th December 2020International S.C.A. Artal10,937,500Open or private purchase$3.20$35,000,000.00
8th December 2020Public Equities, L.P. Invus790,000Open or private purchase$19.00$15,010,000.00
8th December 2020Public Equities, L.P. Invus5,050,911Conversion of derivative$0.00
28th September 2020Christopher J Sobecki996Grant/award etc.$0.00
28th September 2020Raymond Debbane996Grant/award etc.$0.00
29th June 2020Raymond Debbane740Grant/award etc.$0.00
29th June 2020Christopher J Sobecki740Grant/award etc.$0.00
24th June 2020Lonnel Coats2,250Grant/award etc.$0.00
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995.

Ticker: LXRX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1062822
Employees: 184
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.
Red Flags
Red Flag analysis based on Klaus Henselmann / Elisabeth Scherr paper
Fundamentals
Cash at Carrying Value: $87 M (0%)
Inventory, Net: $4 M (-5%)
Other Assets, Current: $9 M (77%)
Assets, Current: $246 M (-27%)
Property, Plant and Equipment, Net: $12 M (-17%)
Other Assets, Noncurrent: $1 M (-12%)
Assets: $323 M (-22%)
Long-term Debt, Current Maturities: $10 M (-5%)
Accounts Payable, Current: $30 M (144%)
Accrued Liabilities, Current: $57 M (36%)
Liabilities, Current: $98 M (49%)
Long-term Debt, Excluding Current Maturities: $235 M (0%)
Other Liabilities, Noncurrent: $862 Th (-21%)
Liabilities: $333 M (10%)
Common Stock, Value, Issued: $108 Th (1%)
Common Stock, Shares, Issued: $108 Th (1%)
Retained Earnings (Accumulated Deficit): $1 B (10%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $312 Th (271%)
Treasury Stock, Value: $48 Th (26%)
Treasury Stock, Shares: $8 Th (94%)
Stockholders' Equity (Parent): $11 M (-90%)
Liabilities and Equity: $323 M (-22%)
Revenue: $25 Th (-24%)
Cost of Revenue: $728 Th (-43%)
Research and Development: $57 M (-49%)
Operating Income/Loss: $65 M (-49%)
EPS (basic): $0.65 (-48%)
Red Flag analysis based on Klaus Henselmann / Elisabeth Scherr paper
News
Generic placeholder
Final Update For My 20/20 Vision For 2020 Dividend Paying Stocks

26th January 2021

Generic placeholder
Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure

14th January 2021

Generic placeholder
Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia

31st December 2020

Generic placeholder
Lexicon Pharmaceuticals Enters Data Collaboration With AC Bioscience

16th December 2020

Generic placeholder
Lexicon Buoyed By Renewed Enthusiasm For The Pipeline

15th December 2020

Generic placeholder
Lexicon Announces Offering of Common Stock

11th December 2020